Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Isradipine
Overview
What is Isradipine?
Isradipine is a calcium antagonist available for oral administration in capsules containing 2.5 mg or 5 mg.
The structural formula of isradipine is:
Chemically, isradipine is 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester. Isradipine is a yellow, fine crystalline powder which is odorless or has a faint characteristic odor. Isradipine is practically insoluble in water (<10 mg/L at 37ºC), but is soluble in ethanol and freely soluble in acetone, chloroform and methylene chloride.
Active Ingredient:
Inactive Ingredients:
What does Isradipine look like?
What are the available doses of Isradipine?
Sorry No records found.
What should I talk to my health care provider before I take Isradipine?
Sorry No records found
How should I use Isradipine?
The dosage of isradipine should be individualized. The recommended initial dose of isradipine is 2.5 mg b.i.d. alone or in combination with a thiazide diuretic. An antihypertensive response usually occurs within 2-3 hours. Maximal response may require 2-4 weeks. If a satisfactory reduction in blood pressure does not occur after this period, the dose may be adjusted in increments of 5 mg/day at 2-4 week intervals up to a maximum of 20 mg/day. Most patients, however, show no additional response to doses above 10 mg/day, and adverse effects are increased in frequency above 10 mg/day.
The bioavailability of isradipine (increased AUC) is increased in elderly patients (above 65 years of age), patients with hepatic functional impairment, and patients with mild renal impairment. Ordinarily, the starting dose should still be 2.5 mg b.i.d. in these patients.
What interacts with Isradipine?
Sorry No Records found
What are the warnings of Isradipine?
Sorry No Records found
What are the precautions of Isradipine?
Sorry No Records found
What are the side effects of Isradipine?
Sorry No records found
What should I look out for while using Isradipine?
Isradipine is contraindicated in individuals who have shown hypersensitivity to any of the ingredients in the formulation.
None
What might happen if I take too much Isradipine?
Minimal empirical data are available on isradipine overdosage. Three individual suicide attempts with dosages of isradipine reported to be from 20 mg up to 100 mg resulted in lethargy, sinus tachycardia and, in the case of the person ingesting 100 mg, transient hypotension which responded to fluid therapy. A foreign report of the ingestion of 200 mg of isradipine with ethanol resulted only in flushing, tachycardia with ST depression on ECG, and hypotension, all of which were reversible. The ingestion of 5 mg of isradipine by a 22-month old child and the accidental ingestion of 100 mg of isradipine by a 58-year old female did not result in any sequelae.
Available data suggest that, as with other dihydropyridines, overdosage with isradipine might result in excessive peripheral vasodilatation with subsequent marked and probably prolonged systemic hypotension, and tachycardia. Emesis, gastric lavage, administration of activated charcoal followed in 30 minutes by a saline cathartic would be reasonable therapy. Isradipine is highly protein-bound and not removed by hemodialysis. Overdosage characterized by clinically significant hypotension should be treated with active cardiovascular support including monitoring of cardiac and respiratory function, elevation of lower extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor (such as epinephrine, norepinephrine, or levarterenol) may be helpful in restoring a normotensive state, provided that there is no contraindication to its use.
Refractory hypotension or AV conduction disturbances may be treated with intravenous calcium salts, or glucagon. Cimetidine should be withheld in such instances due to the risk of further increasing plasma isradipine levels.
Significant lethality was observed in mice given oral doses of over 200 mg/kg and rabbits given about 50 mg/kg of isradipine. Rats tolerated doses of over 2000 mg/kg without effects on survival.
How should I store and handle Isradipine?
Pharmacist:Isradipine Capsules, USP2.5 mg 5 mg Store and Dispense Rx OnlyManufactured by: Horsham, PA 19044For: Parsippany, NJ 07054 USA Revised: June 2014224868Isradipine Capsules, USP2.5 mg 5 mg Store and Dispense Rx OnlyManufactured by: Horsham, PA 19044For: Parsippany, NJ 07054 USA Revised: June 2014224868Isradipine Capsules, USP2.5 mg 5 mg Store and Dispense Rx OnlyManufactured by: Horsham, PA 19044For: Parsippany, NJ 07054 USA Revised: June 2014224868Isradipine Capsules, USP2.5 mg 5 mg Store and Dispense Rx OnlyManufactured by: Horsham, PA 19044For: Parsippany, NJ 07054 USA Revised: June 2014224868Isradipine Capsules, USP2.5 mg 5 mg Store and Dispense Rx OnlyManufactured by: Horsham, PA 19044For: Parsippany, NJ 07054 USA Revised: June 2014224868Isradipine Capsules, USP2.5 mg 5 mg Store and Dispense Rx OnlyManufactured by: Horsham, PA 19044For: Parsippany, NJ 07054 USA Revised: June 2014224868Isradipine Capsules, USP2.5 mg 5 mg Store and Dispense Rx OnlyManufactured by: Horsham, PA 19044For: Parsippany, NJ 07054 USA Revised: June 2014224868Isradipine Capsules, USP2.5 mg 5 mg Store and Dispense Rx OnlyManufactured by: Horsham, PA 19044For: Parsippany, NJ 07054 USA Revised: June 2014224868Isradipine Capsules, USP2.5 mg 5 mg Store and Dispense Rx OnlyManufactured by: Horsham, PA 19044For: Parsippany, NJ 07054 USA Revised: June 2014224868
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Isradipine is a dihydropyridine calcium channel blocker. It binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and smooth muscle. The effects observed in mechanistic experiments and studied in intact animals and man are compatible with this mechanism of action and are typical of the class.
Except for diuretic activity, the mechanism of which is not clearly understood, the pharmacodynamic effects of isradipine observed in whole animals can also be explained by calcium channel blocking activity, especially dilating effects in arterioles which reduce systemic resistance and lower blood pressure, with a small increase in resting heart rate. Although like other dihydropyridine calcium channel blockers, isradipine has negative inotropic effects studies conducted in intact anesthetized animals have shown that the vasodilating effect occurs at doses lower than those which affect contractility. In patients with normal ventricular function, isradipine’s afterload reducing properties lead to some increase in cardiac output.
Effects in patients with impaired ventricular function have not been fully studied.
Non-Clinical Toxicology
Isradipine is contraindicated in individuals who have shown hypersensitivity to any of the ingredients in the formulation.None
in vitro,
In multiple dose U.S. studies in hypertension, 1228 patients received isradipine alone or in combination with other agents, principally a thiazide diuretic, 934 of them in controlled comparisons with placebo or active agents. An additional 652 patients (which includes 374 normal volunteers) received isradipine in U.S. studies of conditions other than hypertension, and 1321 patients received isradipine in non-U.S. studies. About 500 patients received isradipine in long-term hypertension studies, 410 of them for at least 6 months. The adverse reaction rates given below are principally based on controlled hypertension studies, but rarer serious events are derived from all exposures to isradipine, including foreign marketing experience.
Most adverse reactions were mild and related to the vasodilatory effects of isradipine (dizziness, edema, palpitations, flushing, tachycardia), and many were transient. About 5% of isradipine patients left studies prematurely because of adverse reactions (vs. 3% of placebo patients and 6% of active control patients), principally due to headache, edema, dizziness, palpitations, and gastrointestinal disturbances.
The following table shows the most common adverse reactions, volunteered or elicited, considered by the investigator to be at least possibly drug related. The results for the isradipine treated patients are presented for all doses pooled together (reported by 1% or greater of patients receiving any dose of isradipine), and also for the two treatment regimens most applicable to the treatment of hypertension with isradipine: (1) initial and maintenance dose of 2.5 mg b.i.d., and (2) initial dose of 2.5 mg b.i.d. followed by maintenance dose of 5 mg b.i.d.
†Initial dose of 2.5 mg b.i.d. followed by maintenance dose of 5 mg b.i.d.
†† Initial dose of 2.5 mg b.i.d. followed by sequential titration to 5 mg b.i.d., 7.5 mg b.i.d., and maintenance dose of 10 mg b.i.d.
*Propranolol, prazosin, hydrochlorothiazide, enalapril, captopril.
Except for headache, which is not clearly drug-related (see previous table), the more frequent adverse reactions listed show little change, or increase slightly, in frequency over time, as shown in the following table:
Edema, palpitations, fatigue, and flushing appear to be dose-related, especially at the higher doses of 15-20 mg/day.
In open-label, long-term studies of up to two years in duration, the adverse events reported were generally the same as those reported in the short-term controlled trials. The overall frequencies of these adverse events were slightly higher in the long-term than in the controlled studies, but as in the controlled trials most adverse reactions were mild and transient.
The following adverse experiences were reported in 0.5%-1% of the isradipine-treated patients in hypertension studies, or are rare. More serious events from this and other data sources, including postmarketing exposure, are shown in italics. The relationship of these adverse events to isradipine administration is uncertain.
Skin:
urticaria
Musculoskeletal:
Respiratory:
Cardiovascular:
atrial fibrillation, ventricular fibrillation, myocardial infarction, heart failure
Gastrointestinal:
Urogenital:
Nervous System:
syncope
paresthesia
transient ischemic attack, stroke
Autonomic:
Miscellaneous:
leukopenia, elevated liver function tests
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).